293780.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 02:30):

Stats
Today's Volume	15 145.00
Average Volume	139 067
Market Cap	129.11B
EPS	KRW-200.39 ( 2023-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW7.77 (0.13%)

Volume Correlation

Long: -0.24 (neutral)

Short: 0.59 (weak)

Signal:(47.869) Neutral

AptaBio Therapeutics Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AptaBio Therapeutics Inc. Correlation - Currency/Commodity

-0.44
( neutral )

0.11
( neutral )

-0.04
( neutral )

-0.06
( neutral )

-0.33
( neutral )

AptaBio Therapeutics Inc. Financials

Annual	2023
Revenue:	KRW323.87M
Gross Profit:	KRW-421.60M (-130.18 %)
EPS:	KRW-856.45

Q4	2023
Revenue:	KRW289.21M
Gross Profit:	KRW-759.47M (-262.60 %)
EPS:	KRW-372.57

Q3	2023
Revenue:	KRW8.39M
Gross Profit:	KRW8.39M (100.00 %)
EPS:	KRW-186.98

Q2	2023
Revenue:	KRW6.78M
Gross Profit:	KRW6.78M (100.00 %)
EPS:	KRW-96.51

Financial Reports:

No articles found.

AptaBio Therapeutics Inc.

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.